Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CK Life Sciences International Holdings's quarterly market cap
declined
from Jun. 2025 (HK$8,169 Mil) to Dec. 2025 (HK$7,881 Mil) and
declined
from Dec. 2025 (HK$7,881 Mil) to Jun. 2026 (HK$5,478 Mil).
CK Life Sciences International Holdings's annual market cap
declined
from Dec. 2023 (HK$5,959 Mil) to Dec. 2024 (HK$3,941 Mil) but then
increased
from Dec. 2024 (HK$3,941 Mil) to Dec. 2025 (HK$7,881 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CK Life Sciences International Holdings's Enterprise Value for Today is HK$11,467 Mil.
CK Life Sciences International Holdings (HKSE:00775) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CK Life Sciences International Holdings Market Cap Related Terms
CK Life Sciences International Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Market Cap Chart
CK Life Sciences International Holdings Annual Data
HKSE:00775 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Market Cap vs Biotechnology Industry
CK Life Sciences International Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (HKSE:00775) has a Market Cap of HK$5,238 Mil as of Aug. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CK Life Sciences International Holdings and its competitors. According to the industry distribution chart, CK Life Sciences International Holdings ranks #364 out of 1421 companies in the Biotechnology industry, placing it in the top 25.6%.
Is CK Life Sciences International Holdings' Market Cap too high?
CK Life Sciences International Holdings' current Market Cap is HK$5,238 Mil. Based on the distribution chart, CK Life Sciences International Holdings ranks #364 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #364 out of 1421 companies for Market Cap. This puts CK Life Sciences International Holdings in the upper half of its industry. The industry median Market Cap is 119.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.48, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 119.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Market Cap is HK$5,238 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
Based on GuruFocus' analysis, CK Life Sciences International Holdings (HKSE:00775) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.71, compared to a current price of HK$0.55 — trading 23.2% below its estimated fair value. The current Market Cap is HK$5,238 Mil. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CK Life Sciences International Holdings (HKSE:00775), the current Market Cap is HK$5,238 Mil as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (HKSE:00775) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of HK$0.55 is trading 23.2% below its estimated GF Value™ of HK$0.71.
GuruFocus considers CK Life Sciences International Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:00775:
Market Cap: HK$5,238 Mil
GF Value™: HK$0.71 vs. price of HK$0.55 (23.2% below fair value)
No single metric tells the full story. See the HKSE:00775 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for HKSE:00775
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00775 has been successfully added to your 
